JP2009537608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537608A5 JP2009537608A5 JP2009511524A JP2009511524A JP2009537608A5 JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5 JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- light chain
- heavy chain
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 238000010494 dissociation reaction Methods 0.000 claims 7
- 230000005593 dissociations Effects 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 5
- -1 aromatic amino acid Chemical class 0.000 claims 5
- 102000043959 human IL18 Human genes 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 1
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0610438A GB0610438D0 (en) | 2006-05-25 | 2006-05-25 | Immunoglobulins |
| GB0610438.4 | 2006-05-25 | ||
| GB0611046.4 | 2006-06-05 | ||
| GB0611046A GB0611046D0 (en) | 2006-06-05 | 2006-06-05 | Immunoglobulins |
| PCT/EP2007/055029 WO2007137984A2 (en) | 2006-05-25 | 2007-05-23 | Modified humanised anti-interleukin-18 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009537608A JP2009537608A (ja) | 2009-10-29 |
| JP2009537608A5 true JP2009537608A5 (https=) | 2013-07-25 |
| JP5420399B2 JP5420399B2 (ja) | 2014-02-19 |
Family
ID=38476914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511524A Active JP5420399B2 (ja) | 2006-05-25 | 2007-05-23 | 改変型ヒト化抗インターロイキン−18抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8133978B2 (https=) |
| EP (1) | EP2027157B1 (https=) |
| JP (1) | JP5420399B2 (https=) |
| KR (1) | KR101416078B1 (https=) |
| AR (1) | AR061115A1 (https=) |
| AU (1) | AU2007267213B2 (https=) |
| BR (1) | BRPI0711908B8 (https=) |
| CA (1) | CA2652733C (https=) |
| CR (1) | CR10468A (https=) |
| EA (1) | EA017303B1 (https=) |
| ES (1) | ES2514495T3 (https=) |
| IL (1) | IL194995A0 (https=) |
| MA (1) | MA30486B1 (https=) |
| MX (1) | MX2008014842A (https=) |
| MY (1) | MY157173A (https=) |
| NO (1) | NO341921B1 (https=) |
| NZ (1) | NZ572565A (https=) |
| PE (1) | PE20080262A1 (https=) |
| SG (1) | SG172625A1 (https=) |
| TW (1) | TWI422387B (https=) |
| WO (1) | WO2007137984A2 (https=) |
| ZA (1) | ZA200809662B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CA2652733C (en) | 2006-05-25 | 2016-06-21 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| AU2008304748C1 (en) | 2007-09-26 | 2014-06-12 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JP2012500242A (ja) * | 2008-08-18 | 2012-01-05 | グラクソ グループ リミテッド | Il−18アンタゴニストを用いる自己免疫疾患の治療 |
| MX2011001117A (es) | 2008-08-27 | 2011-03-02 | Hoffmann La Roche | Metodo para cribado de anticuerpo de alta afinidad. |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010040736A2 (en) * | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| CN102482344B (zh) | 2009-08-25 | 2014-09-17 | 弗·哈夫曼-拉罗切有限公司 | 速度因子 |
| WO2011098424A2 (en) | 2010-02-09 | 2011-08-18 | Glaxo Group Limited | Treatment of a metabolic disorder |
| WO2011127141A1 (en) * | 2010-04-07 | 2011-10-13 | Abbott Laboratories | TNF-α BINDING PROTEINS |
| AR083937A1 (es) * | 2010-11-23 | 2013-04-10 | Glaxo Group Ltd | Proteinas de union a antigenos |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| US20130149308A1 (en) * | 2011-08-12 | 2013-06-13 | Genentech, Inc. | Antibodies to il-1beta and il-18, for treatment of disease |
| US9376489B2 (en) | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| ES2742413T3 (es) | 2012-11-21 | 2020-02-14 | Km Biologics Co Ltd | Nuevo anticuerpo humano contra IL-18 |
| AU2014265624B2 (en) * | 2013-05-15 | 2019-09-12 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Il−6関連疾患治療用組成物 |
| JP6875683B2 (ja) | 2015-05-19 | 2021-05-26 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
| WO2017076805A1 (en) * | 2015-11-02 | 2017-05-11 | Glaxosmithkline Intellectual Property Development Limited | Use of an inhibitor of il18 for treatment of acute kidney injury |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| EP3698808B1 (en) | 2017-10-20 | 2025-01-01 | Hyogo College Of Medicine | Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Il-6阻害剤を含有する喘息の治療剤 |
| IL287220B2 (en) | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
| JP2023549257A (ja) | 2020-11-18 | 2023-11-22 | ノバルティス アーゲー | Nlrc4-gofインフラマソーム病の処置における使用のための二特異性抗体 |
| EP4371573A4 (en) | 2021-07-13 | 2025-08-20 | National Univ Corporation Tokai National Higher Education And Research System | MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| WO2023056193A2 (en) * | 2021-09-29 | 2023-04-06 | Chimera Bioengineering, Inc. | Il-18 variants and uses thereof |
| AU2024314970A1 (en) | 2023-06-20 | 2026-01-15 | Apollo Ap43 Limited | Anti-il-18 antibody therapy for treating atopic dermatitis |
| WO2025229563A1 (en) * | 2024-05-03 | 2025-11-06 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating inflammatory bowel disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| EP0628639B1 (en) * | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| DE69230545T2 (de) | 1991-08-21 | 2000-07-06 | Novartis Ag, Basel | Antikörperderivate |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| JP2952750B2 (ja) | 1995-02-23 | 1999-09-27 | 株式会社林原生物化学研究所 | モノクローナル抗体 |
| TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
| EP2338915A3 (en) * | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| TWI335336B (https=) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| NZ520122A (en) | 2000-02-21 | 2005-04-29 | Applied Research Systems | Use of IL-18 inhibitors |
| US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| MXPA03003144A (es) * | 2000-10-13 | 2004-12-06 | Biogen Inc | Anticuerpos humanizados anti-lt-??-r. |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| WO2002066063A1 (en) | 2001-02-23 | 2002-08-29 | Nippon Organon K.K. | Remedies for metabolic bone diseases |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| UA78516C2 (en) | 2001-08-10 | 2007-04-10 | Applied Research Systems | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity |
| AU2004235595C1 (en) | 2003-04-30 | 2009-09-24 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| HRP20110657T1 (hr) * | 2004-03-30 | 2011-10-31 | Glaxo Group Limited | Imunoglobulin koji se veže na osm |
| GB0425556D0 (en) | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Novel compounds |
| GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| US20080317710A1 (en) | 2006-02-22 | 2008-12-25 | University Of Zurich | Methods For Treating Autoimmune or Demyelinating Diseases |
| CA2652733C (en) | 2006-05-25 | 2016-06-21 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| JP2012500242A (ja) | 2008-08-18 | 2012-01-05 | グラクソ グループ リミテッド | Il−18アンタゴニストを用いる自己免疫疾患の治療 |
-
2007
- 2007-05-23 CA CA2652733A patent/CA2652733C/en active Active
- 2007-05-23 JP JP2009511524A patent/JP5420399B2/ja active Active
- 2007-05-23 TW TW096118442A patent/TWI422387B/zh not_active IP Right Cessation
- 2007-05-23 MX MX2008014842A patent/MX2008014842A/es active IP Right Grant
- 2007-05-23 AR ARP070102237A patent/AR061115A1/es not_active Application Discontinuation
- 2007-05-23 SG SG2011037421A patent/SG172625A1/en unknown
- 2007-05-23 AU AU2007267213A patent/AU2007267213B2/en not_active Ceased
- 2007-05-23 EP EP07786719.0A patent/EP2027157B1/en active Active
- 2007-05-23 NZ NZ572565A patent/NZ572565A/en not_active IP Right Cessation
- 2007-05-23 EA EA200802182A patent/EA017303B1/ru not_active IP Right Cessation
- 2007-05-23 BR BRPI0711908A patent/BRPI0711908B8/pt active IP Right Grant
- 2007-05-23 PE PE2007000638A patent/PE20080262A1/es not_active Application Discontinuation
- 2007-05-23 KR KR1020087031233A patent/KR101416078B1/ko not_active Expired - Fee Related
- 2007-05-23 ES ES07786719.0T patent/ES2514495T3/es active Active
- 2007-05-23 WO PCT/EP2007/055029 patent/WO2007137984A2/en not_active Ceased
- 2007-05-23 US US11/752,707 patent/US8133978B2/en active Active
- 2007-05-23 MY MYPI20084745A patent/MY157173A/en unknown
-
2008
- 2008-10-30 IL IL194995A patent/IL194995A0/en unknown
- 2008-11-05 NO NO20084650A patent/NO341921B1/no unknown
- 2008-11-12 ZA ZA2008/09662A patent/ZA200809662B/en unknown
- 2008-11-27 CR CR10468A patent/CR10468A/es unknown
- 2008-12-01 MA MA31429A patent/MA30486B1/fr unknown
-
2011
- 2011-12-09 US US13/315,358 patent/US8637018B2/en active Active
-
2013
- 2013-12-19 US US14/133,751 patent/US9499617B2/en active Active
-
2016
- 2016-10-14 US US15/293,823 patent/US20170029497A1/en not_active Abandoned
-
2018
- 2018-10-16 US US16/161,175 patent/US10703814B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537608A5 (https=) | ||
| TWI769537B (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| JP2022061992A5 (https=) | ||
| Almagro et al. | Humanization of antibodies | |
| JP2015504306A5 (https=) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JP2014534242A5 (https=) | ||
| JP2018526981A5 (https=) | ||
| US20100261620A1 (en) | Methods of Humanizing and Affinity-Maturing Antibodies | |
| JP2010524435A5 (https=) | ||
| RU2012130840A (ru) | Соединения | |
| RU2004135103A (ru) | Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике | |
| RU2009128064A (ru) | Антитела к cd44 | |
| AU2013291937A1 (en) | Antibodies to highly conserved targets | |
| RU2008137763A (ru) | Связующий элемент для рецептора gm-csf | |
| CN110612308A (zh) | 制备pH依赖性抗体的方法 | |
| TW201014602A (en) | Prostaglandin E2 binding proteins and uses thereof | |
| JP2010535012A5 (https=) | ||
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2013509158A5 (https=) | ||
| TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
| US20110223176A1 (en) | Basigin binding proteins |